Englander Institute for Precision Medicine
Found 887 results
Author Title Type [ Year(Asc)]
Filters: Clinical-trials-corner-issue-10(1) is   [Clear All Filters]
2022
Mordoh A, Aris M, Carri I, Bravo AInés, Podaza E, Pardo JCarlos Tri, Cueto GRubén, Barrio MMarcela, Mordoh J.  2022.  An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases.. Front Immunol. 13:842555.
Batra R, Uni R, Akchurin OM, Alvarez-Mulett S, Gómez-Escobar LG, Patino E, Hoffman KL, Simmons W, Chetnik K, Buyukozkan M et al..  2022.  Urine-based multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.. medRxiv.
Malla M, Loree JM, Kasi PMurtaza, Parikh ARaj.  2022.  Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.. J Clin Oncol. 40(24):2846-2857.
Rajappa P, Eng KW, Bareja R, Bander ED, Yuan M, Dua A, Maachani UBhanu, Snuderl M, Pan H, Zhang T et al..  2022.  Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors.. Neurooncol Adv. 4(1):vdac031.
Gomari DP, Schweickart A, Cerchietti L, Paietta E, Fernandez H, Al-Amin H, Suhre K, Krumsiek J.  2022.  Variational autoencoders learn transferrable representations of metabolomics data.. Commun Biol. 5(1):645.
Brendel M, Getseva V, Assaad MAl, Sigouros M, Sigaras A, Kane T, Khosravi P, Mosquera JMiguel, Elemento O, Hajirasouliha I.  2022.  Weakly-supervised tumor purity prediction from frozen H&E stained slides.. EBioMedicine. 80:104067.
Barratt CLR, Wang C, Baldi E, Toskin I, Kiarie J, Lamb DJ.  2022.  What advances may the future bring to the diagnosis, treatment, and care of male sexual and reproductive health? Fertil Steril. 117(2):258-267.
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M et al..  2022.  What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. Eur Urol. 82(1):6-11.
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2022.  Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 18(35):3867-3874.
Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Netto GJ et al..  2022.  WHO 2022 landscape of papillary and chromophobe renal cell carcinoma.. Histopathology. 81(4):426-438.
Cyrta J, Rosiene J, Bareja R, Kudman S, Zoughbi WAl, Motanagh S, Wilkes DC, Eng K, Zhang T, Sticca E et al..  2022.  Whole-genome characterization of myoepithelial carcinomas of the soft tissue.. Cold Spring Harb Mol Case Stud. 8(7)
Santambrogio L, Franco A.  2022.  The yin/yang balance of the MHC-selfimmunopeptidome.. Front Immunol. 13:1035363.
2021
Clement CC, D'Alessandro A, Thangaswamy S, Chalmers S, Furtado R, Spada S, Mondanelli G, Ianni F, Gehrke S, Gargaro M et al..  2021.  3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine.. Nat Commun. 12(1):4447.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V et al..  2021.  Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.. Lancet Oncol. 22(4):525-537.
Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JLyun, Lim HYeong et al..  2021.  Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.. Eur Urol. 79(3):334-338.
Gjyrezi A, Galletti G, Zhang J, Worroll D, Sigouros M, Kim S, Cooley V, Ballman KV, Ocean AJ, Shah MA et al..  2021.  Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage.. Commun Biol. 4(1):785.
Skaro M, Hill M, Zhou Y, Quinn S, Davis MB, Sboner A, Murph M, Arnold J.  2021.  Are we there yet? A machine learning architecture to predict organotropic metastases. BMC Med Genomics. 14(1):281.
Bhinder B, Gilvary C, Madhukar NS, Elemento O.  2021.  Artificial Intelligence in Cancer Research and Precision Medicine.. Cancer Discov. 11(4):900-915.
Elemento O, Leslie C, Lundin J, Tourassi G.  2021.  Artificial intelligence in cancer research, diagnosis and therapy.. Nat Rev Cancer. 21(12):747-752.
Kepp O, Bezu L, Yamazaki T, Di Virgilio F, Smyth MJ, Kroemer G, Galluzzi L.  2021.  ATP and cancer immunosurveillance.. EMBO J. 40(13):e108130.
Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, San Pedro JManuel Bra, Cadwell K, Cecconi F, Choi AMK et al..  2021.  Autophagy in major human diseases.. EMBO J. 40(19):e108863.
Yamazaki T, San Pedro JManuel Bra, Galluzzi L, Kroemer G, Pietrocola F.  2021.  Autophagy in the cancer-immunity dialogue.. Adv Drug Deliv Rev. 169:40-50.
Grivas P, Agarwal N, Pal S, Kalebasty ARezazadeh, Sridhar SS, Smith J, Devgan G, Sternberg CN, Bellmunt J.  2021.  Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.. Cancer Treat Rev. 97:102187.
Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJasmine, Ching KA, Pu J, Sternberg CN, Petrylak DP, Tambaro R et al..  2021.  Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.. Nat Med. 27(12):2200-2211.
de Wit R, Wülfing C, Castellano D, Kramer G, Eymard J-C, Sternberg CN, Fizazi K, Tombal B, Bamias A, Carles J et al..  2021.  Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.. ESMO Open. 6(5):100241.